Long-term combination antiplatelet therapy after coronary intervention has been recommended as a means to reduce clinical adverse events. The related field of cardiovascular therapy is being transformed continuously due to the emergence of new antiplatelet agents possessing unique properties.

This event is not part of the official ACC Annual Scientific Session and/or the American College of Cardiology’s Innovation in Intervention: i2 Summit in partnership with the Cardiovascular Research Foundation (CRF) as planned by their Program Committees.